The impact of COVID-19 on hospital-based workers influenza vaccination uptake: A two-year retrospective cohort study

OBJECTIVES: This study aimed at exploring 2020/2021 and 2019/2020 seasonal influenza vaccine uptake among healthcare and non‐healthcare workers, hereafter hospital‐based workers (HBWs); examining attitudes and motivations for uptake in the 2020/2021 season; and exploring the amount, types, and sources of information used by HBWs. METHODS: A retrospective cohort study. Socio‐demographics, working profile, working area, and vaccination status data were collected. Motivations for vaccination uptake in the 2020/2021 season were also explored. Descriptive and inferential statistics were used. RESULTS: Overall, uptake increased from 14.8% in 2019/2020 to 31.7% in 2020/2021. Male workers show greater vaccination uptake than their female counterparts (20.4% vs. 12.6% in 2019/2020, and 36.5% vs. 29.8% in 2020/2021). Uptake increased for healthcare assistants (+8.9%), administrative/managerial staff (+17%), nurses/midwives (+17.1%), non‐medical graduate staff (+22.8%), and physicians (+33.2%), while it decreased slightly for resident physicians despite still being one of the most vaccinated categories (−4.6%). Main reasons for vaccination were the desire to protect patients (33.0%) and relatives (51.1%). Lastly, 60.8% of HBWs relied on institutional sources of information; the remainder relied on non‐institutional sources including social media and chatting with colleagues. CONCLUSIONS: Vaccination uptake increased in the 2020/21 season. Tailored educational interventions are required on the impact of influenza in care settings, vaccine efficacy, and vaccination safety. Investments in improving HBWs' reliance on institutional sources, and their ability to find them, are also needed

Complications post renal transplantation: literature focus on BK virus nephropathy and diagnostic tools actually available

Clinical diagnosis of kidney transplants related illnesses is not a simple task. Several studies were conducted to define diseases and complications after renal transplantation, but there are no comprehensive guidelines about diagnostic tools for their prevention and detection

Evidence for surface faulting earthquakes on the Montereale fault system (Abruzzi Apennines, central Italy)

We conducted paleoseismic studies along the Montereale fault system (MFS; central Italy). The MFS shows geomorphological evidence of Late Quaternary activity and falls within the highest seismic hazard zone of central Apennines, between the epicentral areas of two recent earthquake sequences: 2009 L’Aquila and 2016–2017 central Italy. We excavated two trenches along the San Giovanni fault splay of the system, one intercepting the N140° striking bedrock main fault plane and the other cutting two subparallel fault scarps on the colluvial/alluvial deposits on the fault hanging wall. Excavations revealed repeated fault reactivation with surface faulting in prehistorical and historical times. We recognized and dated seven events in the last 26 kyr. The most recent ground-rupturing event (evb1) possibly occurred 650–1,820 AD, consistent with one of the three main shocks that struck the area in 1,703 AD. A previous event (evb2) occurred between 5,330 BC and 730 BC, while older events occurred at 6,590–5,440 BC (evb3), 9,770–6,630 BC (evb4), and 16,860–13,480 BC (evb5). We documented two older displacement events (evb7 and evb6) between 23,780 BC and 16,850 BC. The minimum vertical slip rate at the trench site in the last 28–24 kyr is 0.3–0.4 mm/year. The inferred average recurrence interval for surface-faulting events along the MFS is no longer than ~4 kyr. Based on the surface fault length ranging between 12 and 20 km, earthquakes with ≥M 6.0 are possible for the MFS. The MFS is an independent earthquake source, and its paleoseismic data are fully comparable with those known for faults in central Apennines.Published2758-27766T. Studi di pericolosità sismica e da maremotoJCR Journa

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia

Signaling through the phosphatidylinositol 3-kinase (PI3K) pathway and its downstream effectors, Akt and mechanistic target of rapamycin (mTOR), is aberrantly activated in acute myeloid leukemia (AML) patients, where it contributes to leukemic cell proliferation, survival, and drug-resistance. Thus, inhibiting mTOR signaling in AML blasts could enhance their sensitivity to cytotoxic agents. Preclinical data also suggest that allosteric mTOR inhibition with rapamycin impaired leukemia initiating cells (LICs) function. In this study, we assessed the therapeutic potential of a combination consisting of temsirolimus [an allosteric mTOR complex 1 (mTORC1) inhibitor] with clofarabine, a nucleoside analogue with potent inhibitory effects on both ribonucleotide reductase and DNA polymerase. The drug combination (CLO-TOR) displayed synergistic cytotoxic effects against a panel of AML cell lines and primary cells from AML patients. Treatment with CLO-TOR induced a G0/G1-phase cell cycle arrest, apoptosis, and autophagy. CLO-TOR was pro-apoptotic in an AML patient blast subset (CD34+/CD38−/CD123+), which is enriched in putative leukemia initiating cells (LICs). In summary, the CLO-TOR combination could represent a novel valuable treatment for AML patients, also in light of its efficacy against LICs

Molecular Signature of Biological Aggressiveness in Clear Cell Sarcoma of the Kidney (CCSK)

: Clear cell sarcoma of the kidney (CCSK) is a rare pediatric renal tumor with a worse prognosis than Wilms' tumor. Although recently, BCOR internal tandem duplication (ITD) has been found as a driver mutation in more than 80% of cases, a deep molecular characterization of this tumor is still lacking, as well as its correlation with the clinical course. The aim of this study was to investigate the differential molecular signature between metastatic and localized BCOR-ITD-positive CCSK at diagnosis. Whole-exome sequencing (WES) and whole-transcriptome sequencing (WTS) were performed on six localized and three metastatic BCOR-ITD-positive CCSKs, confirming that this tumor carries a low mutational burden. No significant recurrences of somatic or germline mutations other than BCOR-ITD were identified among the evaluated samples. Supervised analysis of gene expression data showed enrichment of hundreds of genes, with a significant overrepresentation of the MAPK signaling pathway in metastatic cases (p < 0.0001). Within the molecular signature of metastatic CCSK, five genes were highly and significantly over-expressed: FGF3, VEGFA, SPP1, ADM, and JUND. The role of FGF3 in the acquisition of a more aggressive phenotype was investigated in a cell model system obtained by introducing the ITD into the last exon of BCOR by Crispr/Cas9 gene editing of the HEK-293 cell line. Treatment with FGF3 of BCOR-ITD HEK-293 cell line induced a significant increase in cell migration versus both untreated and scramble cell clone. The identification of over-expressed genes in metastatic CCSKs, with a particular focus on FGF3, could offer new prognostic and therapeutic targets in more aggressive cases